<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39421098</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Immunological Enigma: A Case Report of COVID-19 Survival in a Patient With Human Immunodeficiency Virus, Hepatitis C Virus, and Tuberculosis Co-infection.</ArticleTitle><Pagination><StartPage>e69588</StartPage><MedlinePgn>e69588</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e69588</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.69588</ELocationID><Abstract><AbstractText>This case report aims to elucidate the unique clinical course of a 34-year-old male patient diagnosed with human immunodeficiency virus (HIV), chronic hepatitis C, and prior tuberculosis (TB) infections, who subsequently contracted COVID-19. Immunological assessments revealed profound immunosuppression, marked by decreased CD4+ T cells (0.037 x 10⁹/L), alongside mildly elevated IgG levels (16.701 g/L), reflecting both HIV-related immunodeficiency and non-adherence to antiretroviral therapy (ART). Concurrently, the patient tested positive for SARS-CoV-2. Imaging findings demonstrated overlapping characteristics of TB and COVID-19. Timely initiation of specific TB therapy, alongside supportive care and optimized antiretroviral and anti-TB regimens, was implemented. Despite the patient's immunocompromised state and complex medical history, he successfully recovered from COVID-19. Key factors contributing to survival included early TB diagnosis and treatment, comprehensive medical care, careful management of drug interactions, and a potentially effective individual immune response. Notably, no typical features of COVID-19 pneumonia were observed, suggesting that the dual infection may have influenced the clinical presentation. This case underscores the potential for positive outcomes in individuals with complex medical histories, including coexisting infections. Further research into the interplay of multiple infections in such patients is warranted to optimize clinical management strategies and enhance our understanding of COVID-19 within this distinctive population.</AbstractText><CopyrightInformation>Copyright © 2024, Bozhkova et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bozhkova</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Microbiology and Immunology, Plovdiv Medical University, Plovdiv, BGR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrov</LastName><ForeName>Steliyan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Microbiology and Immunology, Plovdiv Medical University, Plovdiv, BGR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velyanova</LastName><ForeName>Tanya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Infectious Disease, St. George University Hospital, Plovdiv, BGR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoycheva</LastName><ForeName>Mariyana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Disease, Plovdiv Medical University, Plovdiv, BGR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murdjeva</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Microbiology and Immunology, Plovdiv Medical University, Plovdiv, BGR.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">co-infection</Keyword><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">hcv</Keyword><Keyword MajorTopicYN="N">hiv</Keyword><Keyword MajorTopicYN="N">immunocompromised</Keyword><Keyword MajorTopicYN="N">survival</Keyword><Keyword MajorTopicYN="N">tb</Keyword></KeywordList><CoiStatement>Human subjects: Consent was obtained or waived by all participants in this study. Commission on Academic Ethics at Plovdiv Medical University issued approval Р-650. The scientific research meets the standards and criteria for scientific rigor and ethics and is consistent with the requirements of the Helsinki Declaration on Ethics in Science, the principles of Good Clinical Practice, and Bulgarian laws and regulations for conducting clinical and scientific research involving human participants. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: This research was funded by the Bulgarian Ministry of Education and Science under the National Program "Young Scientists and Postdoctoral Students-2." Project code: КП-06-Н53/1, Duration of immunological memory after vaccination against COVID-19 - cellular and humoral immunity defined by memory T and B cell subsets. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39421098</ArticleId><ArticleId IdType="pmc">PMC11484182</ArticleId><ArticleId IdType="doi">10.7759/cureus.69588</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. Turtle L, Thorpe M, Drake TM, et al. PLoS Med. 2023;20:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9928075</ArticleId><ArticleId IdType="pubmed">36719907</ArticleId></ArticleIdList></Reference><Reference><Citation>Unveiling COVID-19 treatment strategies for immunocompromised individuals: therapeutic innovations and latest findings. Liu LT, Tsai JJ. Int J Rheum Dis. 2024;27:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">38287550</ArticleId></ArticleIdList></Reference><Reference><Citation>Editorial: therapeutic management of COVID-19 in immunocompromised patients and interaction with the immune response: from preventive to curative strategies. Benotmane I, Solis M. https://doi.org/10.3389/FIMMU.2024.1441199. Front Immunol. 2024;15:1441199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11286558</ArticleId><ArticleId IdType="pubmed">39081312</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus disease-2019 in the immunocompromised host. Bertini CD Jr, Khawaja F, Sheshadri A. Clin Chest Med. 2023;44:395–406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9678818</ArticleId><ArticleId IdType="pubmed">37085228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mycobacterium tuberculosis and interactions with the host immune system: opportunities for nanoparticle based immunotherapeutics and vaccines. Bekale RB, Du Plessis SM, Hsu NJ, et al. Pharm Res. 2019;36:1–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6362825</ArticleId><ArticleId IdType="pubmed">30411187</ArticleId></ArticleIdList></Reference><Reference><Citation>Immune response to Mycobacterium tuberculosis: a narrative review. de Martino M, Lodi L, Galli L, Chiappini E. https://doi.org/10.3389/FPED.2019.00350. Front Pediatr. 2019;7:350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6718705</ArticleId><ArticleId IdType="pubmed">31508399</ArticleId></ArticleIdList></Reference><Reference><Citation>Immune evasion and provocation by Mycobacterium tuberculosis. Chandra P, Grigsby SJ, Philips JA. Nat Rev Microbiol. 2022;20:750–766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9310001</ArticleId><ArticleId IdType="pubmed">35879556</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuberculosis: pathogenesis, current treatment regimens and new drug targets. Alsayed SS, Gunosewoyo H. Int J Mol Sci. 2023;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10049048</ArticleId><ArticleId IdType="pubmed">36982277</ArticleId></ArticleIdList></Reference><Reference><Citation>HIV infection does not alter interferon α/β receptor 2 expression on mucosal immune cells. Ickler J, Francois S, Widera M, Santiago ML, Dittmer U, Sutter K. https://doi.org/10.1371/JOURNAL.PONE.0218905. PLoS One. 2020;15:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6959566</ArticleId><ArticleId IdType="pubmed">31935222</ArticleId></ArticleIdList></Reference><Reference><Citation>Sensor sensibility-HIV-1 and the innate immune response. Yin X, Langer S, Zhang Z, Herbert KM, Yoh S, König R, Chanda SK. https://doi.org/10.3390/CELLS9010254. Cells. 2020;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7016969</ArticleId><ArticleId IdType="pubmed">31968566</ArticleId></ArticleIdList></Reference><Reference><Citation>Human immunodeficiency virus: opportunistic infections and beyond. Siripurapu R, Ota Y. Neuroimaging Clin N Am. 2023;33:147–165.</Citation><ArticleIdList><ArticleId IdType="pubmed">36404041</ArticleId></ArticleIdList></Reference><Reference><Citation>Interferon (IFN) and cellular immune response evoked in RNA-pattern sensing during infection with hepatitis C virus (HCV) Nakai M, Oshiumi H, Funami K, Okamoto M, Matsumoto M, Seya T, Sakamoto N. https://doi.org/10.3390/S151027160. Sensors (Basel) 2015;15:27160–27173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4634469</ArticleId><ArticleId IdType="pubmed">26512676</ArticleId></ArticleIdList></Reference><Reference><Citation>Restoration of HCV-specific immune responses with antiviral therapy: a case for DAA treatment in acute HCV infection. Casey JL, Feld JJ, MacParland SA. Cells. 2019;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6523849</ArticleId><ArticleId IdType="pubmed">30959825</ArticleId></ArticleIdList></Reference><Reference><Citation>B cells in HIV infection and disease. Moir S, Fauci AS. https://doi.org/10.1038/nri2524. Nat Rev Immunol. 2009;9:235–245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779527</ArticleId><ArticleId IdType="pubmed">19319142</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronic hepatitis-C infection in COVID-19 patients is associated with in-hospital mortality. Ronderos D, Omar AM, Abbas H, et al. World J Clin Cases. 2021;9:8749–8762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8546815</ArticleId><ArticleId IdType="pubmed">34734053</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa. https://doi.org/10.1093/CID/CIAA1198. Clin Infect Dis. 2021;73:0–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499501</ArticleId><ArticleId IdType="pubmed">32860699</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug-resistant TB, HIV and Covid-19 co-infection: case reviews from Kwa-Zulu Natal, South Africa. Hassan-Moosa R, Motsomi KW, Narasimmulu R, et al.  https://doi.org/10.2147/IDR.S433695. Infect Drug Resist. 2023;16:7663–7670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10731725</ArticleId><ArticleId IdType="pubmed">38126006</ArticleId></ArticleIdList></Reference><Reference><Citation>The impact of COVID-19 on tuberculosis: challenges and opportunities. Kant S, Tyagi R. https://doi.org/10.1177/20499361211016973. Ther Adv Infect Dis. 2021;8:20499361211016973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8193657</ArticleId><ArticleId IdType="pubmed">34178322</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterns of HIV and SARS-CoV-2 co-infection in Wuhan, China. Guo W, Ming F, Feng Y, et al.  https://doi.org/10.1002/JIA2.25568. J Int AIDS Soc. 2020;23:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323012</ArticleId><ArticleId IdType="pubmed">32697865</ArticleId></ArticleIdList></Reference><Reference><Citation>Protective interplay: Mycobacterium tuberculosis diminishes SARS-CoV-2 severity through innate immune priming. Williams BD, Ferede D, Abdelaal HF, et al. Front Immunol. 2024;15:1424374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11222399</ArticleId><ArticleId IdType="pubmed">38966641</ArticleId></ArticleIdList></Reference><Reference><Citation>Immune interaction between SARS-CoV-2 and Mycobacterium tuberculosis. Booysen P, Wilkinson KA, Sheerin D, Waters R, Coussens AK, Wilkinson RJ. https://doi.org/10.3389/FIMMU.2023.1254206/FULL. Front Immunol. 2023;14:1254206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10569495</ArticleId><ArticleId IdType="pubmed">37841282</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>